Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the proportion of patients who are undergoing Biventricular (BiV) Implantable Cardioverter Defibrillator (ICD) implantation in whom optimization of atrioventricular (AV) delay is not possible due to prolonged inter-atrial/intra-atrial delay. These patients would benefit from left atrial pacing, and if a significant number of patients fall into this group, it may be beneficial to develop a left atrial lead.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pacemaker Utilization and Ventricular Pacing in Patients Undergoing Trans-catheter Aortic Valve Replacement (TAVR)

NCT02994667

Ventricular Flutter Atrioventricular Block Intraventricular Conduction Delay +2 more

COMPLETED

Electrophysiologic HV-interval as a Predicor for Permanent Pacemaker Implantation After TAVI

NCT01801098

Symptomatic Aortic Valve Stenosis

COMPLETED

Clinical Benefit of Rigourous AV Delay Optimization in Patients With a Dual Chamber Pacemaker

NCT01998256

Quality of Life Pacemaker Ddd Permanent Atrial Dysfunction

COMPLETED NA

Biventricular Pacing After Cardiopulmonary Bypass

NCT00498940

Heart Failure

TERMINATED NA

Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI

NCT02700633

TAVI

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective observational study. Patients referred for BiV-ICD implantation or upgrade will be implanted as is routinely done, with the following modifications:

* Electrical readings will be taken at various points in the procedure.
* The RA lead will temporarily be placed on the atrial septum for these readings (normally it is actively fixed to the RA appendage wall). The final RA lead position will be actively fixed to the RA appendage wall as is standard practice.
* The CS lead will be placed in the proximal coronary sinus for these readings prior to passing it distally to pace the LV.
* Patients will undergo transthoracic echocardiography (TTE) 30 days post-procedure. This will be coordinated to coincide with their standard 30-day follow-up appointment.

Conduction times between the left atrium and right atrium (inter-atrial conduction time) will be measured at the time of implant, and left atrial contraction time will be measured by TTE at the follow-up appointment. For patients in whom the inter-atrial conduction time plus the left atrial contraction time is greater than the right-atrial to right-ventricular conduction time, it is not possible to optimize the AV delay. The proportion of patients who fall into this group will be the main endpoint of the study. Patients will be followed for this study until their follow-up appointment and TTE at 30 days post-implant. The total sample size of this study will be 50 patients. We expect to consent approximately 75 patients, expecting that 1/3 will not meet all entrance criteria or will withdraw early.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Have the ability to provide informed consent and willingness to comply with follow-up tests
* QRS duration \> 120 ms
* Ejection fraction \< 35%
* Persistent symptoms of class III or IV heart failure despite a stable and optimized medical regimen
* Normal sinus rhythm or sinus bradycardia